Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection

被引：0

作者：

Yadav, Surekha ^{[1
]}

Kim, Sarasa T. ^{[1
]}

Tuchayi, Abuzar Moradi ^{[1
]}

Jiang, Fei ^{[2
]}

Morley, Amanda ^{[1
]}

Saelee, Rachelle ^{[1
]}

Wang, Yingbing ^{[1
]}

Juarez, Roxanna ^{[1
]}

Lawnh-Heath, Courtney ^{[1
]}

Koshkin, Vadim S. ^{[3
,4
]}

Hope, Thomas A. ^{[1
,4
,5
]}

机构：

[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94115 USA

[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA

[3] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA

[4] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA

[5] San Francisco Vet Affairs VA Med Ctr, Dept Radiol, San Francisco, CA 94121 USA

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

Ga-68-PSMA PET/CT; F-18-DCFPyL-PET/CT; Lu-177-PSMA; radioligand therapy (RLT); mCRPC; patient screening; RESISTANT PROSTATE-CANCER; CLINICAL-TRIALS; OPEN-LABEL; RECOMMENDATIONS; MULTICENTER; OUTCOMES; DESIGN;

D O I：

10.3389/fonc.2024.1382582

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Ga-68-PSMA-11 is recommended for the selection of patients for treatment in the package insert for Lu-177-PSMA-617. We aimed to compare imaging properties and post-treatment outcomes from radioligand therapy (RLT) of patients selected with Ga-68-PSMA-11 and F-18-DCFPyL. Methods: We retrospectively evaluated 80 patients undergoing PSMA RLT, who had pretreatment imaging using either Ga-68-PSMA-11 or F-18-DCFPyL. For both groups, we compared the biodistribution and lesion uptake and the PSA response to treatment. Results: Both agents had comparable biodistribution. Patients initially imaged with F-18-DCFPyL had a higher PSA response (66% vs. 42%), and more patients had a PSA50 response (72% vs. 43%) compared to patients imaged with Ga-68-PSMA-11. Conclusion: F-18-DCFPyL and Ga-68-PSMA-11 had comparable biodistribution and lesion uptake. Patients imaged with F-18-DCFPyL demonstrated clinical benefit to PSMA RLT comparable to those imaged with Ga-68-PSMA-11, and either agent can be used for screening patients.

引用

页数：6

共 21 条

[1] PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler, Wolfgang P.
Eiber, Matthias
Beheshti, Mohsen
Bomanji, Jamshed
Calais, Jeremie
Ceci, Francesco
Cho, Steve Y.
Fanti, Stefano
Giesel, Frederik L.
Goffin, Karolien
Haberkorn, Uwe
Jacene, Heather
Koo, Phillip J.
Kopka, Klaus
Krause, Bernd J.
Lindenberg, Liza
Marcus, Charles
Mottaghy, Felix M.
Oprea-Lager, Daniela E.
Osborne, Joseph R.
Piert, Morand
Rowe, Steven P.
Schoeder, Heiko
Wan, Simon
Wester, Hans-Jurgen
Hope, Thomas A.
Herrmann, Ken
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (05) : 1466 - 1486
[2] Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Fendler, Wolfgang P.
Calais, Jeremie
Eiber, Matthias
Flavell, Robert R.
Mishoe, Ashley
Feng, Felix Y.
Nguyen, Hao G.
Reiter, Robert E.
Rettig, Matthew B.
Okamoto, Shozo
Emmett, Louise
Zacho, Helle D.
Ilhan, Harun
Wetter, Axel
Rischpler, Christoph
Schoder, Heiko
Burger, Irene A.
Gartmann, Jeannine
Smith, Raven
Small, Eric J.
Slavik, Roger
Carroll, Peter R.
Herrmann, Ken
Czernin, Johannes
Hope, Thomas A.
[J]. JAMA ONCOLOGY, 2019, 5 (06) : 856 - 863
[3] Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
Ferreira, Goncalo
Iravani, Amir
Hofman, Michael S.
Hicks, Rodney J.
[J]. CANCER IMAGING, 2019, 19 (1):
[4] Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Fizazi, Karim
Herrmann, Ken
Krause, Bernd J.
Rahbar, Kambiz
Chi, Kim N.
Morris, Michael J.
Sartor, Oliver
Tagawa, Scott T.
Kendi, Ayse T.
Vogelzang, Nicholas
Calais, Jeremie
Nagarajah, James
Wei, Xiao X.
Koshkin, Vadim S.
Beauregard, Jean-Mathieu
Chang, Brian
Ghouse, Ray
DeSilvio, Michelle
Messmann, Richard A.
de Bono, Johann
[J]. LANCET ONCOLOGY, 2023, 24 (06) : 597 - 610
[5] Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Gafita, Andrei
Calais, Jeremie
Grogan, Tristan R.
Hadaschik, Boris
Wang, Hui
Weber, Manuel
Sandhu, Shahneen
Kratochwil, Clemens
Esfandiari, Rouzbeh
Tauber, Robert
Zeldin, Anna
Rathke, Hendrik
Armstrong, Wesley R.
Robertson, Andrew
Thin, Pan
D'Alessandria, Calogero
Rettig, Matthew B.
Delpassand, Ebrahim S.
Haberkorn, Uwe
Elashoff, David
Herrmann, Ken
Czernin, Johannes
Hofman, Michael S.
Fendler, Wolfgang P.
Eiber, Matthias
[J]. LANCET ONCOLOGY, 2021, 22 (08) : 1115 - 1125
[6] Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
Gafita, Andrei
Heck, Matthias M.
Rauscher, Isabel
Tauber, Robert
Cala, Lisena
Franz, Charlott
D'Alessandria, Calogero
Retz, Margitta
Weber, Wolfgang A.
Eiber, Matthias
[J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (10) : 1476 - 1483
[7] Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
Heck, Matthias M.
Tauber, Robert
Schwaiger, Sebastian
Retz, Margitta
D'Alessandria, Calogero
Maurer, Tobias
Gafita, Andrei
Wester, Hans-Juergen
Gschwend, Juergen E.
Weber, Wolfgang A.
Schwaiger, Markus
Knorr, Karina
Eiber, Matthias
[J]. EUROPEAN UROLOGY, 2019, 75 (06) : 920 - 926
[8] Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer
Heilinger, Jan
Weindler, Jasmin
Roth, Katrin Sabine
Krapf, Philipp
Schomaecker, Klaus
Dietlein, Markus
Drzezga, Alexander
Kobe, Carsten
[J]. EJNMMI RESEARCH, 2023, 13 (01)
[9] [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Hofman, Michael S.
Emmett, Louise
Sandhu, Shahneen
Iravani, Amir
Joshua, Anthony M.
Goh, Jeffrey C.
Pattison, David A.
Tan, Thean Hsiang
Kirkwood, Ian D.
Ng, Siobhan
Francis, Roslyn J.
Gedye, Craig
Rutherford, Natalie K.
Weickhardt, Andrew
Scott, Andrew M.
Lee, Sze-Ting
Kwan, Edmond M.
Azad, Arun A.
Ramdave, Shakher
Redfern, Andrew D.
Macdonald, William
Guminski, Alex
Hsiao, Edward
Chua, Wei
Lin, Peter
Zhang, Alison Y.
McJannett, Margaret M.
Stockler, Martin R.
Violet, John A.
Williams, Scott G.
Martin, Andrew J.
Davis, Ian D.
[J]. LANCET, 2021, 397 (10276) : 797 - 804
[10] Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Hofman, Michael S.
Lawrentschuk, Nathan
Francis, Roslyn J.
Tang, Colin
Vela, Ian
Thomas, Paul
Rutherford, Natalie
Martin, Jarad M.
Frydenberg, Mark
Shakher, Ramdave
Wong, Lih-Ming
Taubman, Kim
Lee, Sze Ting
Hsiao, Edward
Roach, Paul
Nottage, Michelle
Kirkwood, Ian
Hayne, Dickon
Link, Emma
Marusic, Petra
Matera, Anetta
Herschtal, Alan
Iravani, Amir
Hicks, Rodney J.
Williams, Scott
Murphy, Declan G.
[J]. LANCET, 2020, 395 (10231) : 1208 - 1216

← 1 2 3 →